The Board of Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announce the appointment of Matrix Corporate Capital LLP as joint broker with immediate effect.
For further information contact:
Professor Lindy Durrant - Scancell Holdings Plc
John Bick/Kirsty Corcoran - Hansard Communications
Ross Andrews/Tom Rowley - Zeus Capital - Nominated Adviser/Joint Broker
Robert Naylor/Stephen Waterman - Matrix Corporate Capital LLP - Joint Broker
Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.
The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.
Thu, 25 Apr 2019 10:56:00
The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck
Thu, 25 Apr 2019 12:20:00
It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia
Mon, 08 Apr 2019 08:20:00
Sign up to our newsletter to stay up to date with Scancell